Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2013  |  Volume : 40  |  Issue : 2  |  Page : 61-63

Pioglitazone: A boon we know less about


Department of Internal Medicine, Princess Durru Shehvar Children's and General Hospital, Purana Haveli, Hyderabad, India

Correspondence Address:
Dilip Gude
Department of Internal Medicine, Princess Durru Shehvar Children's and General Hospital, Hyderabad
India
Login to access the Email id

Source of Support: Durru Shehvar Children's and General Hospital Hyderabad, AP, India, Conflict of Interest: None


DOI: 10.4103/0974-5009.115471

Rights and Permissions

Pioglitazone is a thiazolidinedione that has significant extra-glycemic benefits most promising of which is its anti-atherogenicity. Pioglitazone may be cardioprotective interfering with atherosclerosis at various points such as atherogenesis, plaque inflammation, plaque rupture and hemostatic disturbances (i.e., thrombus/embolism formation), and microangiopathy. The far reaching effects of pioglitazone and its extra-glycemic benefits warrant a better place for it in the plethora of drugs that a diabetic is treated with. A review of literature is presented.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2046    
    Printed67    
    Emailed0    
    PDF Downloaded313    
    Comments [Add]    

Recommend this journal